When given over two decades, Cerezyme (imiglucerase) was effective at easing most symptoms of Gaucher disease type 1…
Articles by Joana Carvalho
A single infusion of AVR-RD-02, Avrobio’s experimental gene therapy for Gaucher disease type 1, was able to…
Liver steatosis, a condition characterized by the buildup of fatty tissue inside the liver, is common in adults with…
Centogene and Evotec have expanded their collaboration agreement to focus on the development of new treatments for…
Lysogene has entered into a collaborative research agreement with Yeda Research and Development, a commercial branch of the…
Arimoclomol, Orphazyme’s investigational therapy for Gaucher disease and other disorders, leads to clinically meaningful, dose-dependent reductions…
Using a non-invasive high-resolution imaging method, physicians found that long-term treatment with Cerezyme (imiglucerase) followed by a switch to…
Although standard therapies for Gaucher disease (GD) usually reduce liver damage, some forms of treatment — particularly enzyme…
Components of the RANK pathway — a biological pathway that acts as a bridge between the immune and skeletal…
Non-motor symptoms, such as cognitive impairments and depression, may be used as early predictors of parkinsonism in Gaucher disease…